Literature DB >> 11488819

Minocycline as a therapeutic option in bullous pemphigoid.

W J Loo1, G Kirtschig, F Wojnarowska.   

Abstract

We present a retrospective analysis of patients with bullous pemphigoid (BP) treated with minocycline in the Department of Dermatology, Churchill Hospital, Oxford between July 1986 and May 2000. More than 200 patients with BP were seen in clinic during the review period. Of these, 22 patients were treated with minocycline, mostly as adjuvant therapy. The response to treatment was assessed by clinical improvement and whether the dose of concurrent immunosuppressive drugs was subsequently reduced. A major response was seen in six patients, a minor response in 11 and no response was seen in five patients. Minocycline was discontinued in four patients because of the occurrence of side-effects. Overall analysis revealed marked clinical benefits of minocycline in BP. However, this is a non-placebo controlled study and should now be followed by a prospective double-blind controlled clinical trial.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488819     DOI: 10.1046/j.1365-2230.2001.00838.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  6 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.

Authors:  Meital Oren-Shabtai; Noa Kremer; Moshe Lapidoth; Eran Sharon; Lihi Atzmony; Adi Nosrati; Emmilia Hodak; Daniel Mimouni; Assi Levi
Journal:  Drugs Aging       Date:  2020-11-24       Impact factor: 3.923

3.  Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis.

Authors:  Xin-Xing Jin; Xue Wang; Ying Shan; Si-Zhe Li; Qun Xu; Hong-Zhong Jin; Ya-Gang Zuo
Journal:  Arch Dermatol Res       Date:  2021-03-28       Impact factor: 3.017

4.  Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.

Authors:  Kathrine R Tan; Alan J Magill; Monica E Parise; Paul M Arguin
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

5.  Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.

Authors:  Parvin Ataie-Kachoie; David L Morris; Mohammad H Pourgholami
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

6.  Minocycline induced lupus with yellow colored chylous exudative pleural effusion.

Authors:  Daniel Starobin; Vladimir Guller; Alexander Gurevich; Sari Tal
Journal:  Respir Med Case Rep       Date:  2017-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.